Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 5/20 | 0.58 |
| ▸ | MERTK | Q12866 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11478987 | 1.00 | HCAR3 (0.58) | HCAR3MERTKEPHX2LMNAPOLB | |
| SCHEMBL11460577 | 1.00 | HCAR3 (0.58) | HCAR3MERTKEPHX2LMNAPOLB | |
| SCHEMBL11465510 | 1.00 | HCAR3 (0.58) | HCAR3MERTKEPHX2LMNAPOLB | |
| SCHEMBL11461585 | 1.00 | HCAR3 (0.58) | HCAR3MERTKEPHX2LMNAPOLB | |
| SCHEMBL1663449 | 0.98 | HCAR3 (0.60) | HCAR3MERTKEPHX2LMNAPOLB | |
| SCHEMBL28691867 | 0.94 | HCAR3 (0.60) | HCAR3MERTKEPHX2LMNAPOLB | |
| SCHEMBL11462469 | 0.92 | HCAR3 (0.51) | HCAR3MERTKEPHX2LMNAPOLB | |
| SCHEMBL11462467 | 0.92 | HCAR3 (0.51) | HCAR3MERTKEPHX2LMNAPOLB | |
| SCHEMBL1542507 | 0.90 | HCAR3 (0.58) | HCAR3MERTKLMNASRD5A2LTA4H | |
| SCHEMBL4940251 | 0.87 | LMNA (0.51) | HCAR3EPHX2LMNAPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110313158-A1 | Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-12-22 | — | — | US | claimed |
| WO-2010097815-A2 | A TWO COMPONENT RECYCLABLE HETEROGENEOUS CATALYST, PROCESS FOR PREPARATION THEREOF AND ITS USE FOR PREPARATION OF AMINES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-09-02 | — | — | WO | claimed |
| US-4227014-A | ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-10-07 | — | — | US | claimed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| WO-2025086591-A1 | ROTIGOTINE PRODRUG DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 烟台药物研究所 | 2025-05-01 | — | — | WO | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-111386118-B | Combination pharmaceutical agents as RSV inhibitors | 英安塔制药有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2023-03-23 | — | — | US | disclosed |
| WO-2015042561-A1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & COMPANY (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20150087758-A1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & COMPANY | 2015-03-26 | — | — | US | disclosed |
| US-20110313158-A1 | Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-12-22 | — | — | US | disclosed |
| WO-2010097815-A2 | A TWO COMPONENT RECYCLABLE HETEROGENEOUS CATALYST, PROCESS FOR PREPARATION THEREOF AND ITS USE FOR PREPARATION OF AMINES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-09-02 | — | — | WO | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-4423051-A | ANTIATHEROSCLEROTIC AGENTS AND HYPOLIPIDEMIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
| US-4227014-A | ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
| US-4105791-A | Hypolipidemic cycloalkylaminobenzoic acids | THE DOW CHEMICAL COMPANY (US) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | HCAR3 725/4885MERTK 2798/4885EPHX2 1891/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | HCAR3 725/4885MERTK 2798/4885EPHX2 1891/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | HCAR3 725/4885MERTK 2798/4885EPHX2 1891/4885 |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | HCAR3 725/4885MERTK 2798/4885EPHX2 1891/4885 |
| US-20110313158-A1 | Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines | HCN2, RAC2, HCN1 | HCAR3 2694/4885MERTK 4004/4885EPHX2 121/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | HCAR3 2461/4885MERTK 3551/4885EPHX2 4072/4885 |
| US-20150087758-A1 | THERMOPLASTIC POLYMER COMPOSITION | ERCC4, SMCHD1, XRCC5 | HCAR3 4564/4885MERTK 4717/4885EPHX2 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.